76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Roivant Sciences Ltd
Closed
SectorHealthcare
11.42 -1.89
Overview
Share price change
24h
Min
11.38
Max
11.7
Income | -278M -252M |
|---|---|
Sales | -1.4M 7.6M |
EPS | -0.29 |
Profit margin | -3,333.884 |
Employees | 750 |
EBITDA | -9.2M -284M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +38.65% upside |
Market Cap | 313M 7.9B |
|---|---|
Previous open | 13.31 |
Previous close | 11.42 |
News Sentiment
By Acuity
50%
50%
154 / 376 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Roivant Sciences Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Roivant Sciences Ltd Forecast
Price Target
By TipRanks
38.65% upside
12 Months Forecast
Average 16 USD 38.65%
High 19 USD
Low 12 USD
Based on 8 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.
Sentiment
By Acuity
154 / 376 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
$
About Roivant Sciences Ltd
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
